Aberrant Alternative Splicing is Another Hallmark of Cancer

Overview

Journal Int J Cell Biol

Publisher Wiley

Specialty Cell Biology

Date 2013 Oct 9

PMID 24101931

Citations 96

Authors

Michael Ladomery

Affiliations

Soon will be listed here.

Abstract

The vast majority of human genes are alternatively spliced. Not surprisingly, aberrant alternative splicing is increasingly linked to cancer. Splice isoforms often encode proteins that have distinct and even antagonistic properties. The abnormal expression of splice factors and splice factor kinases in cancer changes the alternative splicing of critically important pre-mRNAs. Aberrant alternative splicing should be added to the growing list of cancer hallmarks.

Citing Articles

From viruses to cancer: exploring the role of the hepatitis C virus NS3 protein in carcinogenesis.

Martineau C, Rivard N, Bisaillon M Infect Agent Cancer. 2024; 19(1):40.

PMID: 39192306 PMC: 11351854. DOI: 10.1186/s13027-024-00606-2.

Splicing Machinery Is Impaired in Oral Squamous Cell Carcinomas and Linked to Key Pathophysiological Features.

Sanjuan-Sanjuan A, Alors-Perez E, Sanchez-Frias M, Monserrat-Barbudo J, Falguera Uceda M, Heredero-Jung S Int J Mol Sci. 2024; 25(13).

PMID: 39000035 PMC: 11240936. DOI: 10.3390/ijms25136929.

MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression.

Salib A, Jayatilleke N, Seneviratne J, Mayoh C, De Preter K, Speleman F Oncogene. 2023; 43(5):363-377.

PMID: 38049564 PMC: 10824661. DOI: 10.1038/s41388-023-02897-y.

SGC-CLK-1: A chemical probe for the Cdc2-like kinases CLK1, CLK2, and CLK4.

Tiek D, Wells C, Schroder M, Song X, Alamillo-Ferrer C, Goenka A Curr Res Chem Biol. 2023; 3.

PMID: 38009092 PMC: 10673624. DOI: 10.1016/j.crchbi.2023.100045.

Comprehensive analysis of alternative splicing across multiple transcriptomic cohorts reveals prognostic signatures in prostate cancer.

Mou Z, Spencer J, McGrath J, Harries L Hum Genomics. 2023; 17(1):97.

PMID: 37924098 PMC: 10623736. DOI: 10.1186/s40246-023-00545-w.

References

Pan Q, Shai O, Lee L, Frey B, Blencowe B . Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008; 40(12):1413-5. DOI: 10.1038/ng.259. View

Das S, Anczukow O, Akerman M, Krainer A . Oncogenic splicing factor SRSF1 is a critical transcriptional target of MYC. Cell Rep. 2012; 1(2):110-7. PMC: 3334311. DOI: 10.1016/j.celrep.2011.12.001. View

Plowman S, Arends M, Brownstein D, Luo F, Devenney P, Rose L . The K-Ras 4A isoform promotes apoptosis but does not affect either lifespan or spontaneous tumor incidence in aging mice. Exp Cell Res. 2005; 312(1):16-26. DOI: 10.1016/j.yexcr.2005.10.004. View

Bourdon J . p53 and its isoforms in cancer. Br J Cancer. 2007; 97(3):277-82. PMC: 2360320. DOI: 10.1038/sj.bjc.6603886. View

DOrazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S . Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol. 2002; 4(1):11-9. DOI: 10.1038/ncb714. View

Hayes G, Carrigan P, Miller L . Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res. 2007; 67(5):2072-80. DOI: 10.1158/0008-5472.CAN-06-2969. View

De Craene B, Berx G . Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013; 13(2):97-110. DOI: 10.1038/nrc3447. View

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

Venables J . Unbalanced alternative splicing and its significance in cancer. Bioessays. 2006; 28(4):378-86. DOI: 10.1002/bies.20390. View

10.

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

11.

Vaupel P, Mayer A . Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26(2):225-39. DOI: 10.1007/s10555-007-9055-1. View

12.

Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z . AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013; 17(1):113-24. PMC: 3545102. DOI: 10.1016/j.cmet.2012.12.001. View

13.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

14.

Karni R, de Stanchina E, Lowe S, Sinha R, Mu D, Krainer A . The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol. 2007; 14(3):185-93. PMC: 4595851. DOI: 10.1038/nsmb1209. View

15.

Anczukow O, Rosenberg A, Akerman M, Das S, Zhan L, Karni R . The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation. Nat Struct Mol Biol. 2012; 19(2):220-8. PMC: 3272117. DOI: 10.1038/nsmb.2207. View

16.

Ghigna C, Moroni M, Porta C, Riva S, Biamonti G . Altered expression of heterogenous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomas. Cancer Res. 1998; 58(24):5818-24. View

17.

Amin E, Oltean S, Hua J, Gammons M, Hamdollah-Zadeh M, Welsh G . WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell. 2011; 20(6):768-80. PMC: 3574979. DOI: 10.1016/j.ccr.2011.10.016. View

18.

Goncalves V, Theisen P, Antunes O, Medeira A, Ramos J, Jordan P . A missense mutation in the APC tumor suppressor gene disrupts an ASF/SF2 splicing enhancer motif and causes pathogenic skipping of exon 14. Mutat Res. 2008; 662(1-2):33-6. DOI: 10.1016/j.mrfmmm.2008.12.001. View

19.

Miura K, Fujibuchi W, Sasaki I . Alternative pre-mRNA splicing in digestive tract malignancy. Cancer Sci. 2010; 102(2):309-16. DOI: 10.1111/j.1349-7006.2010.01797.x. View

20.

Akaike Y, Kurokawa K, Kajita K, Kuwano Y, Masuda K, Nishida K . Skipping of an alternative intron in the srsf1 3' untranslated region increases transcript stability. J Med Invest. 2011; 58(3-4):180-7. DOI: 10.2152/jmi.58.180. View